Table 1.
Association between SChLAP1 expression by ISH and selected clinicopathologic characteristics among men diagnosed with prostate cancer between 1983 and 2011 in a combined PHS (n = 330) and HPFS (n = 607) cohort
| Characteristic | Overall | SChLAP1 ISH score |
p value a | |
|---|---|---|---|---|
| Low (<100) | High (≥100) | |||
| Participants, n (%) | 937 (100) | 848 (90.5) | 89 (9.5) | |
| Age at diagnosis, yr (mean ± SD) | 66.1 ± 5.9 | 66.0 ± 5.9 | 67.2 ± 5.5 | 0.07 |
| BMI at diagnosis, kg/m2 (mean ± SD) | 25.8 ± 3.5 | 25.9 ± 3.5 | 25.3 ± 3.0 | 0.18 |
| Median PSA at diagnosis, ng/ml (IQR) | 6.5 (4.7–10.0) | 6.5 (4.7–10.0) | 6.0 (4.3–9.7) | 0.35 |
| Gleason score | ||||
| ≤6 | 165 (17.6) | 161 (19.0) | 4 (4.5) | <0.0001 |
| 3 + 4 | 334 (35.7) | 323 (38.1) | 11 (12.4) | |
| 4 + 3 | 227 (24.2) | 193 (22.8) | 34 (38.2) | |
| 8–10 | 211 (22.5) | 171 (20.2) | 40 (44.9) | |
| Pathologic stage, n (%) | ||||
| T2N0/NxM0/Mx | 607 (71.0) | 567 (73.1) | 40 (50.6) | <0.0001 |
| T3N0/NxM0/Mx | 221 (26.0) | 187 (24.2) | 34 (43.0) | |
| T4N1M1 | 25 (3.0) | 20 (2.6) | 5 (6.3) | |
| Clinical stage, n (%) | ||||
| T1/T2N0/NxM0/Mx | 868 (94.3) | 792 (95.2) | 76 (85.4) | 0.002 |
| T3N0/NxM0/Mx | 32 (3.5) | 23 (2.8) | 9 (10.1) | |
| T4/N1/M1 | 21 (2.3) | 17 (2.0) | 4 (4.5) | |
| Specimen type, n (%) | ||||
| Radical prostatectomy | 882 (94.1) | 800 (94.3) | 82 (92.1) | 0.40 |
| TURP | 55 (5.9) | 48 (5.7) | 7 (7.9) | |
| PTEN IHC status, n (%) | ||||
| Intact | 640 (83.0) | 595 (86.1) | 45 (56.3) | <0.0001 |
| Loss | 131 (17.0) | 96 (13.9) | 35 (43.8) | |
PHS = Physicians’ Health Study; HPFS = Health Professionals Follow-up Study; ISH = in situ hybridization; BMI = body mass index; SD = standard deviation; PSA = prostate-specific antigen; TURP = transurethral resection of the prostate; IHC = immunohistochemistry.
Age and BMI at diagnosis between SChLAP1 groups were compared using Student’s t test; PSA level at diagnosis was compared using the Wilcoxon rank-sum test; specimen type and PTEN IHC status were compared using the χ2 test; and Gleason score, pathologic stage, and clinical stage were compared using the Cochran-Armitage test for trends.